Simon Cancer Center, Indiana University Health Indianapolis will be administering this second and unprecedented round of treatments starting early September 2024. I was one of the original clinical trial patients at the University of Chicago in 2021-22. My response was miraculous. It was identified as PMSA 617 Lu177 which has now been approved in the US under the name Pluvicto. I was given just a few months to live with extensive stage 4 metastatic prostate cancer just prior to starting. It has now been more than 2 years before tumors were growing again and PSA rose. The IUH and U of C oncologists knew each other. The repeat is essentially considered another trial, although not a formal trial, as we find no patient data on repeating the treatment.
Other options were considered, but this seems to be the best for me. I've had most all standard protocol treatments, and more for 10 years.